A Phase 1b/2 Trial with Tasquinimod in Patients with Myelofibrosis (primary, Post-PV or PostET) Refractory to or Intolerant for JAK2 Inhibition: the TasqForce Trial

The goal of this clinical trial is to learn if therapy can be improved in patients with myelofibrosis (MF) who have primary resistance or who have progressed after treatment with a Janus kinase (JAK) inhibitor or are intolerant for this category of drugs.
The main questions it aims to answer are:
* To evaluate the feasibility and safety of once daily dose of tasquinimod for 24 weeks (6 cycles)
* To determine the optimal dose
Patients will be treated once daily with tasquinimod for a maximum period of 24 weeks (6 cycles).
During the study most (diagnostic) procedures are part of the standard of care. Different from standard of care:
* Participation may lead to extra visits to the outpatient clinic
* Additional blood will be drawn when blood is already taken per standard of care
* Bone marrow sampling at entry and at the end of the trial
* MRI scans (or CT-scans) have to be performed
* Quality-of-life questionnaires have to be filled out

Start Date15 Oct 2024

Sponsor / Collaborator

Hemato-Oncologie voor Volwassenen Nederland

NCT06327100 / RecruitingPhase 2IIT

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.

Start Date01 Aug 2024

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

ACTRN12621000016831 / Not yet recruitingPhase 2

A randomized, double-blind, placebo-controlled phase II trial to evaluate the efficacy of tasquinimod in reducing the time taken for a 2-point decrease in admission status.in adults with COVID-19

Start Date15 Dec 2022

Sponsor / Collaborator

Hunter Medical Research Institute

100 Clinical Results associated with Tasquinimod

100 Translational Medicine associated with Tasquinimod

100 Patents (Medical) associated with Tasquinimod

Literatures (Medical) associated with Tasquinimod

01 Jun 2024·Bioactive Materials

Enhanced osteochondral regeneration with a 3D-Printed biomimetic scaffold featuring a calcified interfacial layer

Article

Author: Hu, Bin ; Yu, Mingzhao ; Wu, Di ; Yu, Qingxiao ; Yin, Wenjing ; Zheng, Kaiwen ; Wei, Xiaojuan ; Deng, Jue ; Zhang, Changqing

The integrative regeneration of both articular cartilage and subchondral bone remains an unmet clinical need due to the difficulties of mimicking spatial complexity in native osteochondral tissues for artificial implants. Layer-by-layer fabrication strategies, such as 3D printing, have emerged as a promising technology replicating the stratified zonal architecture and varying microstructures and mechanical properties. However, the dynamic and circulating physiological environments, such as mass transportation or cell migration, usually distort the pre-confined biological properties in the layered implants, leading to undistinguished spatial variations and subsequently inefficient regenerations. This study introduced a biomimetic calcified interfacial layer into the scaffold as a compact barrier between a cartilage layer and a subchondral bone layer to facilitate osteogenic-chondrogenic repair. The calcified interfacial layer consisting of compact polycaprolactone (PCL), nano-hydroxyapatite, and tasquinimod (TA) can physically and biologically separate the cartilage layer (TA-mixed, chondrocytes-load gelatin methacrylate) from the subchondral bond layer (porous PCL). This introduction preserved the as-designed independent biological environment in each layer for both cartilage and bone regeneration, successfully inhibiting vascular invasion into the cartilage layer and preventing hyaluronic cartilage calcification owing to devascularization of TA. The improved integrative regeneration of cartilage and subchondral bone was validated through gross examination, micro-computed tomography (micro-CT), and histological and immunohistochemical analyses based on an in vivo rat model. Moreover, gene and protein expression studies identified a key role of Caveolin (CAV-1) in promoting angiogenesis through the Wnt/β-catenin pathway and indicated that TA in the calcified layer blocked angiogenesis by inhibiting CAV-1.

01 Apr 2024·Phytotherapy Research

Berberine ameliorates contrast‐induced acute kidney injury by regulating HDAC4‐FoxO3a axis‐induced autophagy: In vivo and in vitro

Article

Author: Yu, Ran ; Song, Jian ; Xiao, Yao ; Wu, Caixia ; Zhou, Suqin ; Wang, Wanpeng ; Chen, Jiajia ; Chen, Haoyu ; Pan, Yan ; Zuo, Zhi ; Li, Qingju

AbstractIn hospitals, contrast‐induced acute kidney injury (CI‐AKI) is a major cause of renal failure. This study evaluates berberine's (BBR) renal protection and its potential HDAC4 mechanism. CI‐AKI in rats was induced with 10 mL kg−1 ioversol. Rats were divided into five groups: Ctrl, BBR, CI‐AKI, CI‐AKI + BBR, and CI‐AKI + Tasq. The renal function of CI‐AKI rats was determined by measuring serum creatinine and blood urea nitrogen. Histopathological changes and apoptosis of renal tubular epithelial cells were observed by HE and terminal deoxynucleotidyl transferase (TdTase)‐mediated dUTP‐biotin nick end labeling (TUNEL) staining. Transmission electron microscopy was used to observe autophagic structures. In vitro, a CI‐AKI cell model was created with ioversol‐treated HK‐2 cells. Treatments included BBR, Rapa, HCQ, and Tasq. Analyses focused on proteins and genes associated with kidney injury, apoptosis, autophagy, and the HDAC4‐FoxO3a axis. BBR showed significant protective effects against CI‐AKI both in vivo and in vitro. It inhibited apoptosis by increasing Bcl‐2 protein levels and decreasing Bax levels. BBR also activated autophagy, as indicated by changes in autophagy‐related proteins and autophagic flux. The study further revealed that the contrast agent ioversol increased the expression of HDAC4, which led to elevated levels of phosphorylated FoxO3a (p‐FoxO3a) and acetylated FoxO3a (Ac‐FoxO3a). However, BBR inhibited HDAC4 expression, resulting in decreased levels of p‐FoxO3a and Ac‐FoxO3a. This activation of autophagy‐related genes, regulated by the transcription factor FoxO3a, played a role in BBR's protective effects. BBR, a traditional Chinese medicine, shows promise against CI‐AKI. It may counteract CI‐AKI by modulating HDAC4 and FoxO3a, enhancing autophagy, and limiting apoptosis.

01 Nov 2023·The Prostate

Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.

Article

Author: Coleman, Ilsa M ; Dalrymple, Susan L ; Marc Rosen, David ; Perdew, Gary H ; Murray, Iain A ; Nelson, Peter S ; Akinboye, Emmanuel S ; Isaacs, John T ; Antony, Lizamma ; Brennen, W Nathaniel ; Kostova, Maya ; Denmeade, Samuel R

BACKGROUNDThe quinoline-3-carboxamide, Tasquinimod (TasQ), is orally active as a maintenance therapy with an on-target mechanism-of-action via allosteric binding to HDAC4. This prevents formation of the HDAC4/NCoR1/HDAC3 complex, disrupting HIF-1α transcriptional activation and repressing MEF-2 target genes needed for adaptive survival signaling in the compromised tumor micro environment. In phase 3 clinical testing against metastatic castration-resistant prostate cancer(mCRPC), TasQ (1 mg/day) increased time-to-progression, but not overall survival.METHODSTasQ analogs were chemically synthesized and tested for activity compared to the parental compound. These included HDAC4 enzymatic assays, qRT-PCR and western blot analyses of gene and protein expression following treatment, in vitro and in vivo efficacy against multiple prostate cancer models including PDXs, pharmacokinetic analyses,AHR binding and agonist assays, SPR analyses of binding to HDAC4 and NCoR1, RNAseq analysis of in vivo tumors, 3D endothelial sprouting assays, and a targeted kinase screen. Genetic knockout or knockdown controls were used when appropriate.RESULTSHere, we document that, on this regimen (1 mg/day), TasQ blood levels are 10-fold lower than the optimal concentration (≥2 μM) needed for anticancer activity, suggesting higher daily doses are needed. Unfortunately, we also demonstrate that TasQ is an arylhydrocarbon receptor (AHR) agonist, which binds with an EC50 of 1 μM to produce unwanted off-target side effects. Therefore, we screened a library of TasQ analogsto maximize on-target versus off-target activity. Using this approach, we identified ESATA-20, which has ~10-fold lower AHR agonism and 5-fold greater potency against prostate cancer patient-derived xenografts.CONCLUSIONThis increased therapeuticindex nominates ESATA-20 as a lead candidate forclinical development as an orally active third generation quinoline-3-carboxamide analog thatretains its on-target ability to disrupt HDAC4/HIF-1α/MEF-2-dependent adaptive survival signaling in the compromisedtumor microenvironment found in mCRPC.

News (Medical) associated with Tasquinimod

01 Jun 2022

·www.globenewswire.com

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). In the study, the patients are treated with NAP for 4 consecutive days and with docetaxel at a standard dose on day 5 in 21-day treatment cycles. The first stage of this trial required a minimum of two responses out of ten patients to move to the second stage of the trial, which is now enrolling. For more information about the trial, visit www.clinicaltrials.gov. NCT04880863 We are pleased by these early encouraging observations and are excited to follow the progress of the trial, which is now enrolling in its second stage, says Erik Vahtola, Chief Medical Officer at Active Biotech. Patients with advanced NSCLC who have progressed on CPI and standard chemotherapy currently have limited treatment options and new treatment alternatives are needed.See also www.neotx.com for NeoTX’s communication related to this information. Helén Tuvesson President & CEO For further information, please contact: Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 14.00 pm. CET on June 1, 2022. Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information. About NeoTX NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company’s lead TTS molecule, naptumomab estafenatox is currently in clinical development for advanced solid tumors (clinicaltrials.gov/NCT039883954 and NCT04880863). Please visit www.neotx.com for more information. Naptumomab was licensed from Active Biotech to NeoTX Therapeutics Ltd in 2016. NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement. Active Biotech AB(Corp. Reg. No. 556223-9227)Scheelevägen 22, SE-223 63 Lund, SwedenTel: +46 (0)46 19 20 00 Attachment 220601_phase IIa clinical trial naptumomab in combination with docetaxel

First in ClassImmunotherapySmall molecular drugCollaborate

04 Nov 2021

·www.biospace.com

Active Biotech Interim report January - September 2021

“We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer” THIRD QUARTER IN BRIEF • Active Biotech provided status update of its clinical naptumomab project on July 5 • Active Biotech’s partner NeoTX hosted KOL webinar on overcoming checkpoint inhibitor resistance on July 8 EVENTS AFTER THE END OF THE PERIOD Tasquinimod clinical development in multiple myeloma advanced into combination therapy following completion of the initial phase of the ongoing trial in the US (Oct 3) Active Biotech and NeoTX announced that the first patient had been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) (Oct 20) Financial summary SEK M Jul-Sep Jan-Sep Full-year 2021 2020 2021 2020 2020 Net sales - - - 0.5 6.7 Operating profit/loss -11.3 -8.3 -33.6 -28.2 -32.3 Profit/loss after tax -11.2 -8.2 -33.7 -28.2 -32.2 Earnings per share (SEK) -0.05 -0.05 -0.16 -0.17 -0.19 Cash and cash equivalents (at close of period) 68.4 30.9 26.2 Helén Tuvesson, CEO Tel: +46 (0)46 19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) Scheelevägen 22, SE-223 63 Lund Tel: +46 (0)46 19 20 00 The report is also available at . Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication on November 4, 2021 at 08.30 a.m. CET. Attachment 211104_Interim Report Q3

03 Oct 2021

·www.biospace.com

Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have been treated with increasing doses of tasquinimod, which was generally well tolerated. The optimal dose and schedule of tasquinimod, when used as a single agent in patients with multiple myeloma has been established at 1 mg per day after a one-week run in of 0.5 mg daily. This is similar to the treatment schedule used in previous studies of tasquinimod. The trial will now advance to a previously planned combination part, in which treatment with tasquinimod will be tested in patients with multiple myeloma together with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd). Once an optimal dose and schedule of tasquinimod for the IRd combination is established, an expansion cohort will be recruited to further document the biological activity of tasquinimod in myeloma patients. Key secondary endpoints will include antimyeloma activity using the response criteria of the International Myeloma Working Group. The study is conducted in a partnership with the Abramson Cancer Center of the University of Pennsylvania, with Dr. Dan Vogl as principal investigator. For more information about the study please visit clinical clinicaltrials.gov (NCT04405167). "We are pleased to have concluded the first part of this trial, confirming the previous safety pro tasquinimod in patients with multiple myeloma and defining an optimal dose and schedule for tasquinimod in this patient population. The patients included in this study phase were heavily pre-treated, with a median of 8 prior lines of therapy; 8 of the 10 patients were triple-class refractory to Imids, proteasome inhibitors, and anti-CD38 monoclonal antibodies. While none of the patients formally achieved a partial response, two patients with progressive myeloma at study entry achieved significant periods of stable disease on single-agent tasquinimod therapy. This suggests that tasquinimod has anti-myeloma activity in patients with advanced disease that is resistant to established therapies. These results enable us to advance into the combination part of the study, in which tasquinimod will be combined with a standard anti-myeloma treatment regimen. Our preclinical laboratory models suggest that this combination strategy may be a particularly effective way to utilize tasquinimod in myeloma therapy." says Dr. Dan Vogl, Principal Investigator. “We are enthusiastic to have reached this milestone and can conclude the first phase of this study. Based on the established safety data together with the encouraging anti-myeloma activities observed, we look forward to the continuation of the study. In the coming phase, tasquinimod will be evaluated in combination with ixazomib, lenalidomide, and dexamethasone (IRd), which already are established in the clinical practice. The use of tasquinimod, as a novel class of treatment for multiple myeloma, in combination with treatments used for earlier stage patients, is aligned with our current understanding of the mechanism of action of tasquinimod in these patients. ” says Helén Tuvesson, CEO, Active Biotech AB. Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 21:30 p.m. CET on October 3, 2021. About tasquinimod Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor's ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma. Tasquinimod has previously been studied as an anti-cancer agent in patients with solid cancers, including a phase 3 randomized trial in patients with metastatic prostate cancer. The tolerability of tasquinimod is well-characterized based on these previous experiences. Tasquinimod has demonstrated a clear therapeutic potential in preclinical models of multiple myeloma, when used as a single agent and in combination with standard multiple myeloma therapy. About multiple myeloma Multiple myeloma is an incurable blood cancer in which abnormal plasma cells in the bone marrow grow uncontrollably while other blood forming cells such as white and red blood cells and blood platelets are suppressed. This leads to anemia, infections, destruction of bone tissue and progressive loss of renal function. Despite new treatments have greatly improved survival of multiple myeloma patients, the biological heterogeneity of the disease and the emergence of drug resistance is a major challenge, and the medical need of innovative treatment modalities remains high. In 2017, 81000 new cases of multiple myeloma were diagnosed in the eight major markets. The global sales of drugs for multiple myeloma totaled USD 16 billion in 2017 and sales are expected to increase 48% by 2026 (ref Global Data 2019). Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit for more information. Active Biotech AB (Corp. Reg. No. 556223-9227) Scheelevägen 22, SE-223 63 Lund, Sweden Tel: +46 (0)46 19 20 00 Attachment 211003_Tasquinimod clinical development in multiple myeloma

AntibodyFirst in ClassImmunotherapySmall molecular drugCollaborate

100 Deals associated with Tasquinimod

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tasquinimod	-	DB05861

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-Resistant Prostatic Cancer	Phase 2	PL	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Phase 2	KR	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Phase 2	CL	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Phase 2	LT	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Phase 2	IT	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Preclinical	CL	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Preclinical	IT	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Preclinical	KR	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Preclinical	LT	Active Biotech AB	01 Mar 2011
Castration-Resistant Prostatic Cancer	Preclinical	PL	Active Biotech AB	01 Mar 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04405167 (ASCO2023) Manual	Phase 1	Relapse multiple myeloma	10	tasquinimod	(fjxflgsogc) = 0.5 mg qd x1 wk, then 1 mg qd (a single-agent MTD of 1 mg daily after a 1-week dose escalation) lamasgqnel (qhnuhgdtth ) View more	Positive	26 May 2023
NCT02057666 (TasQ003, CTgov)	Phase 3	Castration-Resistant Prostatic Cancer	146	Tasquinimod (Tasquinimod)	jcswpwjwuo(oseexkejwq) = urqkytzfjw ibwarijxya (akuqlpkttb, ntjstdmltq - wncfgglgpt) View more	-	23 Apr 2021
				Placebo (Placebo)	jcswpwjwuo(oseexkejwq) = lpfvnpahcy ibwarijxya (akuqlpkttb, xhihiosvom - spkddfnkju) View more
NCT01743469 (CTgov)	Phase 2	Metastatic Renal Cell Carcinoma \| Ovarian Cancer \| Neoplasm Metastasis \| Metastatic hepatocellular carcinoma	201	Tasquinimod (Hepatocellular Carcinoma Cohort)	xogtiviqdv(tzzvbsoeka) = jsekotauou tabuxmhniz (zvlpijczzy, kpbylijmnh - yyqykdvljt) View more	-	07 May 2018
				Tasquinimod (Ovarian Carcinoma Cohort)	xogtiviqdv(tzzvbsoeka) = fjbbhjxpyp tabuxmhniz (zvlpijczzy, oasjucbdyk - yplunywpgd) View more
NCT01732549 (Pubmed \| Ann Oncol) Manual	Phase 2	Metastatic castration-resistant prostate cancer First line	144	tasquinimod	(fpvsuxpksk) = qkncdufgco wvzmgmohqu (aphelzgvjg, 24.3 - 53.7) View more	Positive	01 Nov 2017
				Placebo	(fpvsuxpksk) = niazfrheda wvzmgmohqu (aphelzgvjg, 16.1 - 25.9) View more
NCT01732549 (Pubmed)	Phase 2	Metastatic castration-resistant prostate cancer Maintenance	144	Tasquinimod	(omeptniupx) = eknynvcjeb cheszizzrj (jvuuhawkph, 24.3 - 53.7)	Positive	01 Nov 2017
				Placebo	(omeptniupx) = dzegjemypt cheszizzrj (jvuuhawkph, 16.1 - 25.9)
NCT01743469 (Pubmed \| Target Oncol)	Phase 2	Stomach Cancer	201	Tasquinimod (Hepatocellular cancer)	(vuddxgzulo) = jruptvmrbw jetcpxdvlp (xrbsqqehbt )	Negative	01 Oct 2017
				Tasquinimod (Ovarian cancer)	(vuddxgzulo) = fsydotfmqr jetcpxdvlp (xrbsqqehbt )
NCT01732549 (CTgov)	Phase 2	Castration-Resistant Prostatic Cancer	144	Tasquinimod (Tasquinimod)	xyixcghqup(tbkymmwjfc) = ctztqexkpy xboodojfza (rcnwrsaigj, jufchkfdmw - wsiksuxuyr) View more	-	03 Oct 2016
				Placebo (Placebo)	xyixcghqup(tbkymmwjfc) = ftvvqunmhz xboodojfza (rcnwrsaigj, ccokestugc - hoaqvcdcpt) View more
NCT01234311 (Pubmed \| J Urol)	Phase 3	Metastatic castration-resistant prostate cancer	1,245	Tasquinimod	(utknjtmzxc) = apekqlcput lbjrcazhvs (bhtqlcgjnd, 19.5 - 23.0) View more	Positive	01 Aug 2016
				Placebo	(utknjtmzxc) = brygxkysuc lbjrcazhvs (bhtqlcgjnd, 21.4 - 26.9) View more
NCT02159950 (CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Castration-Resistant Prostatic Cancer \| Metastatic castration-resistant prostate cancer \| Metastatic Prostate Carcinoma	2	Laboratory Biomarker Analysis+Sipuleucel-T (Arm I (Sipuleucel-T))	hyfngynqln(yqpnboqope) = oufngpuhwv uunogyylor (bjzxgqkfce, epfzsdskva - uzhzabhxvp) View more	-	20 May 2016
				Laboratory Biomarker Analysis+Tasquinimod+Sipuleucel-T (Arm II (Tasquinimod, Sipuleucel-T))	aqupkulwqd(jkxbmjiikk) = kakswfozmy osqtkfcmvy (sblaixdwnr, cjmjmyjwbh - kocxdiadyh) View more
NCT01732549 (ASCO_GU2016)	Phase 2	Castration-Resistant Prostatic Cancer Maintenance	144	Tasquinimod	(fhyuwzouva) = TEAEs ( ≥ Grade 3): TASQ (51%); PBO (26%) vwllhhtqiv (jeylztofjt ) View more	Positive	10 Jan 2016
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis